Microbiological Characterization and Antibiotic Resistance Profiling of Providencia Spp,: An Emerging Pathogen Isolated From Urinary Tract Infections
NCT ID: NCT07204769
Last Updated: 2025-10-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
241 participants
OBSERVATIONAL
2026-05-01
2027-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Isolation and identification of Providencia spp. from UTIs.
2. Genotypic confirmation of Providencia isolates.
3. Determination of antimicrobial sensitivity patterns of isolated Providencia spp.
4. Characterization of some virulence factors of Providencia spp.
5. Molecular characterization of multidrug-resistance gene antibiotics.
6. Determination of risk factors for Providencia UTIs.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Urine Alkalinization for UTI in Women: RCT
NCT07202832
Urinary Infection in Pregnant Women with Urinary Infection
NCT06752161
Standard Antibiotic Versus Enhanced Prophylactic Measures on Rate of Urinary Tract Infection After Flexible Ureteroscopy
NCT04731090
Urinary Tract Infection in Patients With Chronic Kidney Disease
NCT05674942
Analysis of Bacterial Multidrug Tolerance in Patients Prone to Urinary Tract Infections
NCT06724588
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
International surveillance studies report that Providencia accounts for \~1-2% of urinary isolates, with higher prevalence (up to 6-12%) in catheter-associated infection.
The Providencia genus, nestled within the Enterobacterales order as part of Proteus and Morganella relatives, consists of Gram-negative bacteria that are adept at producing urease .
The genus includes 14 distinct species, with Providencia rettgeri, Providencia stuartii, Providencia alcalifaciens, and Providencia hangzhouensis standing out due to their pronounced relevance to human infections. Renowned for their association with urinary tract infections, these pathogens also possess the capability to inflict a broader spectrum of severe ailments, such as ocular diseases,peritonitis, neonatal septicemia or bloodstream infections and meningitis.
Providencia stuartii is able to adhere to and invade HeLa-M epithelial cell line.
They form biofilms and have several virulence genes . Providencia spp. may be susceptible to third- and fourth-generation cephalosporins, aztreonam, imipenem, and meropenem. Providencia species have variable susceptibilities to fluoroquinolones, aminoglycosides, and trimethoprim- sulfamethoxazole (TMP-SMX). Generally, Providencia spp. are frequently resistant to tetracyclines, penicillins, and first- and second- generation cephalosporins .
Providencia spp.are intrinsically resistant to polymyxins and tigecycline, which are considered last- resort antibiotics for other resistant pathogens .
In Egypt, several studies have investigated the prevalence of UTI pathogens, consistently reporting E. coli, Klebsiella spp., and Proteus spp. as the most frequent isolates .
However, no published Egyptian data specifically describe the prevalence, antimicrobial resistance patterns, or clinical significance of Providencia spp. in UTIs.
This gap highlights the need for focused research on Providencia in the Egyptian context. Studying its frequency, antibiotic resistance mechanisms, and clinical relevance would not only provide novel insights but also contribute to improving diagnosis, empirical therapy, and infection control strategies in Egyptian hospitals .
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Antibiotic sensitivity
Molecular characterization of multidrug-resistance gene antibiotics.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2. Patients with any anatomical abnormalities in the urinary tract C) Patients having UTI by gram +ve organisms.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Aya Tareq Diab
Teaching assistant at Medical microbiology and Immunology department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Aya Tareq Diab, Bachelor's degree
Role: PRINCIPAL_INVESTIGATOR
Assiut University
Prof: Mona Hussein Abdel-Rahim, PhD
Role: STUDY_DIRECTOR
Assiut University
Dr. Rawhia Fathy Abdel Hamid, Doctorate
Role: STUDY_CHAIR
Assiut University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Assiut University
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Çetin ET, et al. Providencia spp. in nosocomial urinary infections. Turk J Med Sci. 1998;28(1):59-62
Ewing WH. The tribe Proteeae: its nomenclature and taxonomy. Int J Syst Evol Microbiol. 1962;12(3):93-102
Charbek EPN. Providencia infections treatment & management: medical care, surgical care, consultations. Medscape. 2019
Rose WE, Rybak MJ. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy. 2006 Aug;26(8):1099-110. doi: 10.1592/phco.26.8.1099.
Guidone GHM, Cardozo JG, Silva LC, Sanches MS, Galhardi LCF, Kobayashi RKT, Vespero EC, Rocha SPD. Epidemiology and characterization of Providencia stuartii isolated from hospitalized patients in southern Brazil: a possible emerging pathogen. Access Microbiol. 2023 Oct 18;5(10):000652.v4. doi: 10.1099/acmi.0.000652.v4. eCollection 2023.
Kurmasheva N, Vorobiev V, Sharipova M, Efremova T, Mardanova A. The Potential Virulence Factors of Providencia stuartii: Motility, Adherence, and Invasion. Biomed Res Int. 2018 Feb 21;2018:3589135. doi: 10.1155/2018/3589135. eCollection 2018.
Dong X, Xiang Y, Yang P, Wang S, Yan W, Yuan Y, Zhou S, Zhou K, Liu J, Zhang Y. Novel Providencia xianensis sp. nov.: A multidrug-resistant species identified in clinical infections. Eur J Clin Microbiol Infect Dis. 2024 Jul;43(7):1461-1467. doi: 10.1007/s10096-024-04821-y. Epub 2024 May 7.
O'Hara CM, Brenner FW, Miller JM. Classification, identification, and clinical significance of Proteus, Providencia, and Morganella. Clin Microbiol Rev. 2000 Oct;13(4):534-46. doi: 10.1128/CMR.13.4.534.
Wie SH. Clinical significance of Providencia bacteremia or bacteriuria. Korean J Intern Med. 2015 Mar;30(2):167-9. doi: 10.3904/kjim.2015.30.2.167. Epub 2015 Feb 27. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Providencia UTI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.